Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
| Business Activity | PASS |
| Debt Ratio (2.52%) | FAIL |
| Cash Ratio (1.70%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-05 | -0.13 | Pending | -- |
| 2026-05-15 | -0.17 | -0.20 | -17.3% |
| 2026-03-17 | -0.20 | -0.21 | -7.3% |
| 2025-11-05 | -0.20 | -0.21 | -6.5% |
| 2025-08-05 | -0.18 | -0.17 | +5.8% |
| 2025-05-15 | -0.19 | -0.16 | +16.2% |
| 2025-03-13 | -0.17 | -0.15 | +10.7% |
| 2024-11-07 | -0.16 | -0.14 | +11.2% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $17.0M | -$46.7M | -$43.7M | — | -$44.9M | -0.20 |
| 2025-12-31 | $13.8M | -$47.2M | -$44.3M | — | -$46.0M | -0.21 |
| 2025-09-30 | $13.3M | -$48.2M | -$45.3M | — | -$41.6M | -0.21 |
| 2025-06-30 | $11.5M | -$38.3M | -$35.3M | — | -$38.8M | -0.17 |
| 2025-03-31 | $9.9M | -$36.6M | -$33.5M | — | -$36.8M | -0.16 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-01-02 | HASNAIN FAHEEM | Chief Executive Officer | 280,000 | -- |
| 2026-01-02 | GIRAUDO BRYAN M. | Chief Operating Officer | 115,750 | -- |
| 2026-01-02 | PETERSON CARYN | Officer | 84,500 | -- |
| 2026-01-02 | ARANDA RICHARD | Officer | 93,750 | -- |
| 2026-01-02 | CHRISTIAN WAAGE | Officer | 84,500 | -- |
| 2026-01-02 | SMITH ROBERT PAUL JR | Officer | 93,750 | -- |
| 2025-10-01 | HASNAIN FAHEEM | Chief Executive Officer | 437,500 | -- |
| 2025-10-01 | GIRAUDO BRYAN M. | Chief Operating Officer | 181,250 | -- |
| 2025-10-01 | PETERSON CARYN | Officer | 125,000 | -- |
| 2025-10-01 | ARANDA RICHARD | Officer | 162,500 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 16.8M | $3.5M | 0.1% |
| Kalehua Capital Management LLC | 10.2M | $2.2M | 0.0% |
| AQR Capital Management, LLC | 10.1M | $2.1M | 0.0% |
| Vanguard Capital Management LLC | 9.4M | $2.0M | 0.0% |
| Arch Venture Management, Llc | 8.1M | $1.7M | 0.0% |
| Octagon Capital Advisors LP | 7.8M | $1.6M | 0.0% |
| Samsara BioCapital, LLC | 7.2M | $1.5M | 0.0% |
| Balyasny Asset Management LP | 5.9M | $1.2M | 0.0% |
| Acadian Asset Management. LLC | 5.3M | $1.1M | 0.0% |
| Siren, L.L.C. | 5.2M | $1.1M | 0.0% |
$153.0M
-0.31
2.151
6
$48.5M
$202.9M
2.71
5.86
0.2%
161
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-05 | $-0.13 | Pending | — |
| 2026-05-15 | $-0.17 | $-0.20 | -17.3% |
| 2026-03-17 | $-0.20 | $-0.21 | -7.3% |
| 2025-11-05 | $-0.20 | $-0.21 | -6.5% |
| 2025-08-05 | $-0.18 | $-0.17 | +5.8% |
| 2025-05-15 | $-0.19 | $-0.16 | +16.2% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($4.46, 5 analysts) | |||
| 10 | $3.44 | +$41.10 (1197%) | 82.2R |
| 50 | $17.18 | +$205.50 (1197%) | 82.2R |
| 100 | $34.36 | +$411.00 (1197%) | 82.2R |
- High beta (2.15) — amplifies market moves by 2.15x
- Elevated short interest (5.86 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| SCL | 0.407 |
| UPL.NS | 0.319 |
| AERO | 0.305 |
| JMAT.L | 0.292 |
| JMPLY | 0.292 |
| Ticker | Correlation |
|---|---|
| ESTERAD.BH | -0.281 |
| VRE | -0.212 |
| ALMANAR.KW | -0.192 |
| 4543.T | -0.184 |
| BMMI.BH | -0.157 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.